MedTrace Logo

Duration of Protection: GSK DTaP Vaccines

NCT02447978 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2015-11-02

No results posted yet for this study

Summary

The purpose of this study is to assess duration of protection for GSK DTaP vaccines in preventing pertussis.

Conditions

  • Diphtheria
  • Acellular Pertussis
  • Tetanus

Interventions

BIOLOGICAL

Infanrix

Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.

BIOLOGICAL

Pediarix

Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

BIOLOGICAL

Kinrix

Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
47 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447978 on ClinicalTrials.gov